$AMGN News

Does Amgen (AMGN) Have Enough Cash Flow To Justify Its Price?

AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS

ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data

Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript

Amgen’s Imdelltra Cut Lung Cancer Deaths by 58%. Is It Already in the Stock?

Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress - Slideshow

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

Amgen (AMGN) Reports Positive Phase 3 TEZSPIRE Results In Eosinophilic Esophagitis

Here's Why Amgen (AMGN) Fell More Than Broader Market

Oppenheimer Maintains Outperform on Amgen, Raises Price Target to $480

At Amgen, Sustainability Is A Companywide Commitment

Amgen (AMGN) Gains As Market Dips: What You Should Know

Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?

Amgen (AMGN) Sales Grew 10%, but Can Earnings Catch Up to the Price?

Barclays Maintains Equal-Weight on Amgen, Raises Price Target to $400

AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026

Amgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points

AstraZeneca And Amgen's TEZSPIRE Met Co-Primary Endpoints In Phase III EoE Trial

How Earnings Beat At Amgen Stock Has Changed Its Investment Story